KY Biotechnology & Medical Research

Crescent Biopharma Inc (CBIO)

Track

Over the past 90 days, Crescent Biopharma Inc. saw eight insider transactions. Fairmount Funds Management LLC executed a significant purchase of $12.38 million in shares on July 16, 2026. Conversely, several executives, including the CEO and CFO, conducted planned sales totaling approximately $1.23 million on June 22, 2026, following the company's recent earnings report.
Ticker: CBIO Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Crescent Biopharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 16 Jul 2026
Value US$3,335,893.63 | Price 167.57 | Shares 97,217 (+19.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-20 2026-07-16 B Purchase
3.3
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
97,217 +19.9%
167.57
US$3,335,894 		97,217 +19.9% 167.57 US$3,335,894
2026-06-23 2026-06-22 PlS Planned sale
3.0
Scalzo Richard William

Chief Financial Officer

Officer
22,333 -17.1%
446.76
US$1,181,285 		22,333 -17.1% 446.76 US$1,181,285
2026-06-23 2026-06-22 PlS Planned sale
Pinkas Jan

Chief Scientific Officer

Officer
20,671 +38.6%
353.35
US$1,943,668 		20,671 +38.6% 353.35 US$1,943,668
2026-06-23 2026-06-22 PlS Planned sale
Lynch Ryan

See Remarks

Officer
465 -3.2%
17.99
US$8,365 		465 -3.2% 17.99 US$8,365
2026-06-23 2026-06-22 PlS Planned sale
Bispham Barbara Harlin

See Remarks

Officer
1,218 -5.9%
17.99
US$21,912 		1,218 -5.9% 17.99 US$21,912
2026-06-23 2026-06-22 PlS Planned sale
Im Ellie Eunkyung

Chief Medical Officer

Officer
1,219 -5.2%
17.99
US$21,930 		1,219 -5.2% 17.99 US$21,930
2026-06-23 2026-06-22 PlS Planned sale
2.3
Brumm Joshua T

Chief Executive Officer

Executive Director
42,305 -13.1%
17.99
US$761,067 		42,305 -13.1% 17.99 US$761,067
2026-06-23 2026-06-22 PlS Planned sale
1.5
McNeill Jonathan

President and COO

Officer
20,549 -12.9%
17.99
US$369,677 		20,549 -12.9% 17.99 US$369,677
2025-12-08 2025-12-04 B Purchase
3.3
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
1,360,000 +98.0%
13.41
US$18,237,600 		1,360,000 +98.0% 13.41 US$18,237,600
2024-08-09 2024-08-08 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
260,873 -4.0%
0.19
US$50,009 		260,873 -4.0% 0.19 US$50,009
2024-08-09 2024-08-07 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
61,488 -0.9%
0.18
US$11,197 		61,488 -0.9% 0.18 US$11,197
2024-08-07 2024-08-06 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
55,732 -0.8%
0.18
US$10,188 		55,732 -0.8% 0.18 US$10,188
2024-08-07 2024-08-05 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
164,523 -2.4%
0.19
US$30,996 		164,523 -2.4% 0.19 US$30,996
2024-08-05 2024-08-02 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
286,200 -4.0%
0.20
US$57,354 		286,200 -4.0% 0.20 US$57,354
2024-08-05 2024-08-01 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
63,564 -0.9%
0.22
US$13,743 		63,564 -0.9% 0.22 US$13,743
2024-07-30 2024-07-30 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
756,835 -9.5%
0.22
US$167,185 		756,835 -9.5% 0.22 US$167,185
2024-07-30 2024-07-29 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
363,949 -4.4%
0.24
US$85,637 		363,949 -4.4% 0.24 US$85,637
2024-07-30 2024-07-26 S Sale
3.8
Invus Public Equities, L.P.
Large shareholder
258,335 -3.0%
0.24
US$62,440 		258,335 -3.0% 0.24 US$62,440
2024-06-24 2024-06-21 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
115,000 +20.3%
0.27
US$30,716 		115,000 +20.3% 0.27 US$30,716
2024-06-24 2024-06-20 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
190,000 +50.6%
0.25
US$48,108 		190,000 +50.6% 0.25 US$48,108
2024-06-20 2024-06-18 B Purchase
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
17,500 +32.9%
0.25
US$4,335 		17,500 +32.9% 0.25 US$4,335
2023-09-25 2023-09-22 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
30,403 +8.8%
1.38
US$41,956 		30,403 +8.8% 1.38 US$41,956
2023-09-25 2023-09-21 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
35,000 +11.3%
1.38
US$48,300 		35,000 +11.3% 1.38 US$48,300
2023-05-18 2023-05-17 S Sale
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
3,700 -6.5%
1.95
US$7,215 		3,700 -6.5% 1.95 US$7,215
2023-05-17 2023-05-17 PrS Proposed sale
3.4
Hahn Brian M.

Officer

Officer
4,313
1.96
US$8,453 		4,313 1.96 US$8,453
2023-05-11 2023-05-10 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
30,000 +47.4%
1.56
US$46,800 		30,000 +47.4% 1.56 US$46,800
2023-05-09 2023-05-08 B Purchase
2.4
Johnson Bruce S

SVP & Chief Commercial Officer

Officer
13,500 +10.8%
1.57
US$21,195 		13,500 +10.8% 1.57 US$21,195
2023-02-28 2023-02-24 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
100,000 +1.2%
1.70
US$170,000 		100,000 +1.2% 1.70 US$170,000
2023-02-23 2023-02-23 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
200,000 +2.4%
1.75
US$350,760 		200,000 +2.4% 1.75 US$350,760
2023-02-23 2023-02-22 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
150,000 +1.8%
1.79
US$268,995 		150,000 +1.8% 1.79 US$268,995
2023-02-23 2023-02-21 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
50,000 +0.6%
1.85
US$92,500 		50,000 +0.6% 1.85 US$92,500
2023-02-17 2023-02-17 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
200,000 +2.5%
1.71
US$341,000 		200,000 +2.5% 1.71 US$341,000
2023-02-17 2023-02-16 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
315,266 +4.2%
1.68
US$531,129 		315,266 +4.2% 1.68 US$531,129
2023-02-17 2023-02-15 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
1,000,000 +15.2%
2.16
US$2,155,800 		1,000,000 +15.2% 2.16 US$2,155,800
2023-02-13 2023-02-09 B Purchase
3.8
Invus Public Equities, L.P.
Large shareholder
11,451 +0.2%
3.24
US$37,123 		11,451 +0.2% 3.24 US$37,123
2023-01-27 2023-01-26 S Sale
2.4
SANDELL SCOTT D
Large shareholder
1,351,092 -37.7%
3.12
US$4,213,786 		1,351,092 -37.7% 3.12 US$4,213,786
2023-01-27 2023-01-26 S Sale
2.4
SANDELL SCOTT D
Large shareholder
1,648,908 -37.7%
3.12
US$5,142,614 		1,648,908 -37.7% 3.12 US$5,142,614
2023-01-27 2023-01-25 S Sale
2.4
SANDELL SCOTT D
Large shareholder
293,645 -7.6%
3.26
US$958,428 		293,645 -7.6% 3.26 US$958,428
2023-01-27 2023-01-25 S Sale
2.4
SANDELL SCOTT D
Large shareholder
358,371 -7.6%
3.26
US$1,169,687 		358,371 -7.6% 3.26 US$1,169,687
2023-01-06 2023-01-05 S Sale
2.4
SANDELL SCOTT D
Large shareholder
32,139 -0.8%
2.76
US$88,659 		32,139 -0.8% 2.76 US$88,659
2023-01-06 2023-01-05 S Sale
2.4
SANDELL SCOTT D
Large shareholder
39,223 -0.8%
2.76
US$108,201 		39,223 -0.8% 2.76 US$108,201
2023-01-04 2023-01-04 S Sale
2.4
SANDELL SCOTT D
Large shareholder
45,930 -1.2%
2.91
US$133,643 		45,930 -1.2% 2.91 US$133,643
2023-01-04 2023-01-04 S Sale
2.4
SANDELL SCOTT D
Large shareholder
56,054 -1.2%
2.91
US$163,100 		56,054 -1.2% 2.91 US$163,100
2023-01-04 2023-01-03 S Sale
2.4
SANDELL SCOTT D
Large shareholder
78,730 -1.9%
2.99
US$235,411 		78,730 -1.9% 2.99 US$235,411
2023-01-04 2023-01-03 S Sale
2.4
SANDELL SCOTT D
Large shareholder
96,084 -1.9%
2.99
US$287,301 		96,084 -1.9% 2.99 US$287,301
2023-01-04 2022-12-30 S Sale
2.4
SANDELL SCOTT D
Large shareholder
54,645 -1.3%
3.02
US$165,028 		54,645 -1.3% 3.02 US$165,028
2023-01-04 2022-12-30 S Sale
2.4
SANDELL SCOTT D
Large shareholder
66,690 -1.3%
3.02
US$201,404 		66,690 -1.3% 3.02 US$201,404
2022-12-27 2022-12-22 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
110,000 +55.0%
2.25
US$247,500 		110,000 +55.0% 2.25 US$247,500
2022-11-18 2022-11-17 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
20,000 +46.2%
1.87
US$37,400 		20,000 +46.2% 1.87 US$37,400
2022-11-16 2022-11-15 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
100,000 +100.0%
1.66
US$166,000 		100,000 +100.0% 1.66 US$166,000
2022-11-16 2022-11-14 B Purchase
3.5
Rock Edwin

Chief Medical Officer

Officer
100,000 +inf%
1.43
US$143,000 		100,000 +inf% 1.43 US$143,000
2022-11-14 2022-11-11 B Purchase
3.3
PEARSON TIMOTHY R
Non-Executive Director
19,400 +369.5%
1.29
US$25,026 		19,400 +369.5% 1.29 US$25,026
2022-11-14 2022-11-11 B Purchase
3.3
Semerjian Harout

Chief Executive Officer

Executive Director
25,000 +inf%
1.29
US$32,250 		25,000 +inf% 1.29 US$32,250
2022-11-14 2022-11-11 B Purchase
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
20,000 +54.3%
1.06
US$21,200 		20,000 +54.3% 1.06 US$21,200
2022-11-14 2022-11-11 B Purchase
3.8
Girard Armand

SVP, Chief Business Officer

Officer
6,500 +28.7%
1.05
US$6,825 		6,500 +28.7% 1.05 US$6,825
2022-11-14 2022-11-11 B Purchase
3.8
Magnani John L.

SVP of Research, CSO

Officer
45,045 +14.0%
1.17
US$52,703 		45,045 +14.0% 1.17 US$52,703
2022-03-10 2022-03-09 S Sale
3.4
Hahn Brian M.

SVP Finance, CFO

Officer
2,917 -7.3%
1.09
US$3,180 		2,917 -7.3% 1.09 US$3,180
2022-03-10 2022-03-09 S Sale
3.8
Magnani John L.

SVP of Research, CSO

Officer
3,227 -1.0%
1.09
US$3,517 		3,227 -1.0% 1.09 US$3,517
2022-03-10 2022-03-09 S Sale
3.8
Girard Armand

SVP, Chief Business Officer

Officer
2,339 -9.4%
1.09
US$2,550 		2,339 -9.4% 1.09 US$2,550
2021-11-18 2021-11-16 B Purchase
0.5
Andrews Patricia S
Non-Executive Director
40,000 +761.9%
2.05
US$82,000 		40,000 +761.9% 2.05 US$82,000
2020-12-30 2020-12-28 PlS Planned sale
2.3
King Rachel K.

President, CEO

Executive Director
84,176 -19.1%
3.91
US$329,128 		84,176 -19.1% 3.91 US$329,128
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
86,090 +15.8%
2.60
US$223,834 		86,090 +15.8% 2.60 US$223,834
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
506,155 +15.8%
2.60
US$1,316,003 		506,155 +15.8% 2.60 US$1,316,003
2020-11-06 2020-11-04 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
674,492 +15.7%
2.60
US$1,753,679 		674,492 +15.7% 2.60 US$1,753,679
2020-11-03 2020-10-30 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
15,472 +2.9%
2.75
US$42,548 		15,472 +2.9% 2.75 US$42,548
2020-11-03 2020-10-30 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
250,755 +8.5%
2.75
US$689,576 		250,755 +8.5% 2.75 US$689,576
2020-11-03 2020-10-30 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
666,385 +18.3%
2.75
US$1,832,559 		666,385 +18.3% 2.75 US$1,832,559
2020-03-10 2020-03-09 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
20,000 +111.1%
3.40
US$68,000 		20,000 +111.1% 3.40 US$68,000
2019-09-09 2019-09-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
124,956 +30.9%
3.18
US$397,610 		124,956 +30.9% 3.18 US$397,610
2019-09-09 2019-09-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
689,834 +30.4%
3.18
US$2,195,052 		689,834 +30.4% 3.18 US$2,195,052
2019-09-09 2019-09-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
853,956 +30.7%
3.18
US$2,717,288 		853,956 +30.7% 3.18 US$2,717,288
2019-08-15 2019-08-13 B Purchase
2.6
JUNIUS DANIEL M
Non-Executive Director
10,000 +125.0%
3.18
US$31,800 		10,000 +125.0% 3.18 US$31,800
2018-10-18 2018-10-18 S Sale
3.5
Magnani John L.

SVP of Research, CSO

Executive Director
3,527 -4.4%
14.02
US$49,449 		3,527 -4.4% 14.02 US$49,449
2018-10-18 2018-10-17 S Sale
3.5
Magnani John L.

SVP of Research, CSO

Executive Director
7,273 -8.4%
14.00
US$101,822 		7,273 -8.4% 14.00 US$101,822
2018-10-18 2018-10-16 S Sale
3.5
Magnani John L.

SVP of Research, CSO

Executive Director
14,200 -14.1%
14.01
US$198,942 		14,200 -14.1% 14.01 US$198,942
Explore more

More insider trading research around Crescent Biopharma Inc

More insider trades in KY
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity